About NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial
NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial (NDUFS8) is a protein
from Homo sapiens identified by UniProt accession
O00217, 210 residues long.
MolForge cross-references it against 0 known binders and
256 disease associations.
Target properties
| Protein name | NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial |
|---|
| UniProt accession | O00217 |
|---|
| Gene | NDUFS8 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 210 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (256)
Diseases linked to this target (Open Targets).
- mitochondrial complex I deficiency · score 0.70
- Leigh syndrome · score 0.68
- type 2 diabetes mellitus · score 0.61
- diabetes mellitus · score 0.61
- polycystic ovary syndrome · score 0.60
- type 1 diabetes mellitus · score 0.59
- gestational diabetes · score 0.58
- obesity · score 0.57
- neurodegenerative disease · score 0.57
- prediabetes syndrome · score 0.56
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O00217-F1 | alphafold | PREDICTED | 88.03 | — |
Amino-acid sequence (210 residues)
MRCLTTPMLL RALAQAARAG PPGGRSLHSS AVAATYKYVN MQDPEMDMKS VTDRAARTLL WTELFRGLGM TLSYLFREPA TINYPFEKGP LSPRFRGEHA LRRYPSGEER CIACKLCEAI CPAQAITIEA EPRADGSRRT TRYDIDMTKC IYCGFCQEAC PVDAIVEGPN FEFSTETHEE LLYNKEKLLN NGDKWEAEIA ANIQADYLYR
Explore NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets